In the immunogenic model RLS40, DNase I had anti-tumor, antimetastatic, and immunostimulatory effects and significantly modified the neutrophil profile by decreasing the expression of the immunosuppressive markers (Il10, Ccl17) and increasing the expression of the anti-tumor markers (PD-L1, FAS). This evidence concerns the gene CCL17 and neoplasm.